Home›Screener›EWTX›Profile
C
54/100

Edgewise Therapeutics

EWTXCardiomyopathy
← Signals View
Analyst Summary
✓ VERIFIED2026-04-11

Edgewise Therapeutics (EWTX) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[3], including 5 Phase 2[1], 2 Phase 1[2].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
Clinical Trials
7
NCT05291091Becker Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05540860Duchenne Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06066580Becker Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06100887Duchenne Muscular Dystrophy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06347159Hypertrophic Cardiomyopathy
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07177066Healthy Adults
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07324616Hepatic Impairment (HI)
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
Not financial advice. BiotechSign profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-202026-07-17
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Data Provenance
clinical trial7 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR